Keith D. Eaton, MD, PhD
Dr. Keith D. Eaton is a medical oncologist at the Fred Hutchinson Cancer Center in Seattle, Washington. He specializes in treating patients with cancers of the lung, thyroid, head, and neck, as well as those diagnosed with cancer of unknown primary.[1]
Education and Career
Dr. Eaton earned his undergraduate degree at the University of California, San Diego, and remained at UCSD to earn his medical degree.
He then completed his internship and residency in Internal Medicine at the University of Washington and his fellowship in Medical Oncology at the University of Washington/Fred Hutchinson Cancer Research Center.[1]
He is board-certified in Internal Medicine and Medical Oncology and is a member of the American Society of Clinical Oncology.
Dr. Eaton is currently a medical oncologist at the Fred Hutch Cancer Center in Seattle, Washington. He specializes in treating patients with lung cancer, mesothelioma, head and neck cancers, thyroid cancer, adrenal cancer, and the rare condition called cancer of unknown primary.
Dr. Eaton holds the titles of Clinical Director of Thoracic, Head, and Neck Medical Oncology and Medical Director for Quality, Safety, and Value. He is a professor in the Division of Hematology and Oncology at the University of Washington Medical Center.
His patients include those diagnosed with lung cancer and pleural mesothelioma. He is committed to answering all of their questions honestly and educating them about their condition and available treatment protocols so that they can make informed decisions and participate fully in their own care.[1]
Research
Dr. Eaton leads clinical trials investigating novel drug therapies and immunotherapy for the treatment of lung cancer. He is also working with medical colleagues to expand the understanding of cancer’s biology and to develop more targeted treatments.[1]
His recent publications include:[2]
- Impact of institutional interventions on the rate of paclitaxel hypersensitivity reactions. Mark Edward Jao, Amy Ly Indorf, Eve-Michelle Segal, Abby Miske, Keith David Eaton, Trisha Marsolini, Simran Ghuman>; Journal of Oncology Pharmacy Practice. 2024 Jan 1
- Mocetinostat in Combination With Durvalumab for Patients With Advanced NSCLC: Results From a Phase I/II Study. Melissa L Johnson, James Strauss, Manish R Patel, Edward B Garon, Keith D Eaton, Tavette Neskorik, Josée Morin, Richard Chao, Balazs Halmos>; Clinical Lung Cancer. 2023 May 1
- Development of Neuropathic Arthropathy With Entrectinib: Case Report. Nicholas P Giustini, Hanna Oh, Keith D Eaton>; JTO Clinical and Research Reports. 2022 Nov 1
